Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Sponsor

Novartis Pharmaceuticals (Industry)

Overall Status

Completed

CT.gov ID

NCT02144038

Collaborator

(none)

Enrollment

Locations

Arms

15.2

Actual Duration (Months)

2.5

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a Phase Ib/II study with the primary purpose of the Phase Ib part being to estimate the MTD and/or recommended phase 2 dose (RP2D) of the combination of LGH447 and BYL719 when administered orally to adult patients with relapsed and refractory multiple myeloma. Once the MTD and/or RP2D is determined for the combination of LGH447 and BYL719, additional patients will be enrolled in the Phase II part to determine whether the combination of LGH447 and BYL719 exhibits improved anti-multiple myeloma activity compared to single agent LGH447. This trial never made it to the Phase II part of the this trial.

Condition or Disease	Intervention/Treatment	Phase
Relapsed and Refractory Multiple Myeloma	Drug: LGH447 Drug: BYL719	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

20 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase Ib/II, Multi-center, Study of Oral LGH447 in Combination With Oral BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Actual Study Start Date :

Jul 23, 2014

Actual Primary Completion Date :

Oct 28, 2015

Actual Study Completion Date :

Oct 28, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Phase Ib: LGH447 + BYL719 Dose-escalation, LGH447 in combinatinon with BYL719	Drug: LGH447 pan-PIM inhibitor Drug: BYL719 PI3K-alpha inhibitor
Experimental: Phase II: LGH447 + BYL719 LGH447 + BYL719 (dosing according to MTD/RP2D from Phase Ib portion of the study)	Drug: LGH447 pan-PIM inhibitor Drug: BYL719 PI3K-alpha inhibitor
Experimental: Phase II: LGH447 alone LGH447 alone (dosing according to single-agent RDE)	Drug: LGH447 pan-PIM inhibitor

Arm

Intervention/Treatment

Experimental: Phase Ib: LGH447 + BYL719

Dose-escalation, LGH447 in combinatinon with BYL719

Drug: LGH447

pan-PIM inhibitor

Drug: BYL719

PI3K-alpha inhibitor

Experimental: Phase II: LGH447 + BYL719

LGH447 + BYL719 (dosing according to MTD/RP2D from Phase Ib portion of the study)

Drug: LGH447

pan-PIM inhibitor

Drug: BYL719

PI3K-alpha inhibitor

Experimental: Phase II: LGH447 alone

LGH447 alone (dosing according to single-agent RDE)

Drug: LGH447

pan-PIM inhibitor

Outcome Measures

Primary Outcome Measures

Phase Ib: Number of Total Dose-limiting Toxicities (DLT) [Cycle 1 (28 days)]
Using a Bayesian logistic regression model (BLRM) to guide dose escalation and predict MTD or determine the RP2D for LGH447 in combination with BYL719 in relapsed and refractory multiple myeloma. The frequency and characteristics of DLTs will be assessed.
Phase II: Overall Response Rate (ORR) as assessed by Investigators [29 months (End of Study)]
The proportion of patients with a confirmed best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as assessed by Investigators using the International Myeloma Working group (IMWG) Criteria with modifications. End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.

Secondary Outcome Measures

Phase II: Percent change of ORR (Overall Response Rate) between the two arms [29 months (End of Study)]
The ORR percent change between the two arms, LGH447 in combination with BYL719 and LGH447 alone, is the parameter of interest. Both observed and Bayesian estimates of ORR percent change along with 80% confidence intervals and credible intervals will be calculated. End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.
Number of participants with adverse events, serious adverse events, changes in laboratory values, and electrocardiograms (ECGs), as a measure of safety and tolerability. [23 months]
Assessments consisted of recording all adverse events (AEs) and serious adverse events (SAEs), the regular monitoring of hematology, blood chemistry, urinalysis, and coagulation parameters, as well as electrocardiograms.
Determine single and multiple dose Pharmacokinetics (PK) profiles [Approximately 8 months]
To determine the single and multiple dose PK profiles of the LGH447 and BYL719 combination (Phase Ib and II) and LGH447 alone (Phase II), by measuring plasma concentrations of LGH447 and BYL719 respectively at different timepoints prior and post study drug combination dosing on several days within cycle 1 and subsequent cycles for all patients in the Phase 1b and for the first 15 patients in each arm in the Phase 2 portion of the study. PK parameters including but not limited to Cmax, AUCinf, AUClast, AUCtau,T1/2, Tmax, Racc, CL/F, and Vz/F
Changes between pre- and post-treatment levels of pS6RP and 4EBP1 levels in bone marrow aspirates and 4EBP1 in peripheral blood [baseline, Cycle 2 Day 1]
Cycle 2 = 28 days; LGH447-mediated target modulation of the PIM pathway will be assessed from the collection of bone marrow biopsy and/or aspirates by flow cytometry, immunohistochemistry, or other methods as deemed appropriate. Decreases in the phosphorylation of markers (eg. S6RP and 4EBP1) will be measured in both pre- and post-dose bone marrow aspirate samples and peripheral blood samples.
Phase II: Absolute difference in ORR [29 months (End of Study)]
Both observed and Bayesian estimates of absolute difference in ORR between the two arms will be calculated. The 80% confidence intervals and credible intervals for the difference will be provided. End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.
Disease Control Rate [29 months (End of Study)]
Proportion of patients with a best overall response of sCR, CR, VGPR, PR, MR, or SD, using International Myeloma Working Group Criteria with modification. End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.
Progression Free Survival [29 months (End of Study)]
Defined as the time from start of treatment to the date of event defined as the first documented PD/relapse, or death due to any cause, whichever comes first. End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.
Time to response [29 months (End of Study)]
The time between date of randomization until first documented best overall response (sCR, CR, VPGR or PR). End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.
Duration of Response [29 months (End of Study)]
Defined as the duration from the first documented onset of PR or better response to the date of documented PD/relapse or death due to multiple myeloma. End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
Patients with a confirmed diagnosis of multiple myeloma who have received two or more lines of therapy and are refractory to their most recent line of therapy, as defined as relapse while on therapy or within 60 days from their last line of therapy. If patient has not received either an immunomodulatory drug (IMID) or proteasome inhibitor as a prior therapy then Investigator must notify Novartis prior to the patient enrollment. Patients who have received a prior bone marrow transplant and otherwise meet the inclusion criteria are eligible for this study
For patients in the Phase II portion of the study, must have measurable disease defined by at least 1 of the following 3 measurements:
Serum M-protein ≥ 0.5 g/dL
Urine M-protein ≥ 200 mg/24 hours OR
Serum free light chain (FLC) > 100 mg/L of involved FLC
All patients must be willing to undergo a mandatory bone marrow aspirate and/or biopsy at baseline for the assessment of biomarker/pharmacodynamics and disease status

Exclusion Criteria:

Systemic antineoplastic therapy (including unconjugated therapeutic antibodies and toxin immunoconjugates) or any experimental therapy within 14 days or 5 half-lives, whichever is shorter, before the first dose of either study drug
Radiotherapy within 14 days before the first dose of either study drug except localized radiation therapy for lytic bone lesions and plasmacytomas
Major surgery within 2 weeks before the first dose of either study drug
Ongoing therapy with chronic or high dose corticosteroids. Low dose steroids (i.e. prednisone ≤ 10 mg or an equivalent steroid dose), inhaled and topical steroids are permitted
Patients who are currently receiving treatment with a prohibited medication that cannot be discontinued at least one week prior to the start of treatment:
Narrow Therapeutic index substrates, strong inhibitors and strong inducers of CYP3A4
Strong Inhibitors of CYP2D6
Narrow therapeutic index substrates of CYP2C8, CYP2C9, CYP2C19 and CYP2D6
Any of the following clinical laboratory results during screening (i.e., within 28 days before the first dose of either study drug):
Absolute neutrophil count (ANC) < 1,000/mm3 without growth factor support within 7 days prior to testing
Platelet count < 75,000 mm3 without transfusion support within 7 days prior to testing
Bilirubin > 1.5 times the upper limit of the normal range (ULN).
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULN.
Calculated creatinine clearance < 30 ml/min according to Cockcroft-Gault equation
Corrected QT interval (QTc) of > 450 milliseconds (ms) in males and > 470 milliseconds (ms) in females on baseline electrocardiogram (ECG) (using Fridericia [QTcF] corrected QT interval

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(SC)	Houston	Texas	United States	77030-4009
2	Seattle Cancer Care Alliance Oncology Dept	Seattle	Washington	United States	98105
3	University of Wisconsin / Paul P. Carbone Comp Cancer Center Dept of Onc.	Madison	Wisconsin	United States	53792-6164
4	Novartis Investigative Site	Prahran	Victoria	Australia	3181
5	Novartis Investigative Site	Heidelberg		Germany	69120
6	Novartis Investigative Site	Kiel		Germany	24105
7	Novartis Investigative Site	Milano	MI	Italy	20133
8	Novartis Investigative Site	Singapore		Singapore	169608